KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insulet (PODD) Gains from Sales and Divestitures (2010 - 2012)

Insulet posted quarterly Gains from Sales and Divestitures of $238134.0 for Q4 2012, up 47.16% year-on-year from $161816.0 in Q1 2012, and up 18.59% on a QoQ basis from $200812.0 in Q3 2012.

Insulet (PODD) has 3 years of Gains from Sales and Divestitures data on file, last reported at $238134.0 in Q4 2012.

  • For the quarter ending Q4 2012, Gains from Sales and Divestitures rose 47.16% year-over-year to $238134.0; the trailing twelve-month figure through Dec 2012 stood at $238134.0 (up 47.16% YoY), and the FY2012 full-year result was $238134.0, up 47.16% from the prior year.
  • Gains from Sales and Divestitures for Q4 2012 stood at $238134.0, up from $200812.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $238134.0 in Q4 2012 and bottomed at $1776.0 in Q4 2010.
  • The 3-year median for Gains from Sales and Divestitures is $176480.5 (2011), against an average of $155834.8.
  • The widest annual swing landed in 2011, when Gains from Sales and Divestitures soared 9011.26%; it then surged 47.16% in 2012.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $1776.0 in 2010, then jumped by 9011.26% to $161816.0 in 2011, then jumped by 47.16% to $238134.0 in 2012.
  • The last three Gains from Sales and Divestitures figures came in at $238134.0 (Q4 2012), $200812.0 (Q3 2012), and $191145.0 (Q2 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Insulet 10.37 Bn 9.89 Bn 529.10 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2012 238,134.00
Dec 31, 2012 238,134.00
Sep 30, 2012 200,812.00
Sep 30, 2012 200,812.00
Jun 30, 2012 191,145.00
Jun 30, 2012 191,145.00
Mar 31, 2012 141,326.00
Mar 31, 2012 141,326.00
Dec 31, 2011 161,816.00
Dec 31, 2011 161,816.00
Dec 31, 2010 1,776.00
Dec 31, 2010 1,776.00